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Abstract
Background: P301S tau transgenic mice show age-dependent accumulation of neurofibrillary tangles in the
brainstem, hippocampus, and neocortex, leading to neuronal loss and cognitive deterioration. However, there is
hitherto only sparse documentation of the role of neuroinflammation in tau mouse models. Thus, we analyzed
longitudinal microglial activation by small animal 18 kDa translocator protein positron-emission-tomography (TSPO
μPET) imaging in vivo, in conjunction with terminal assessment of tau pathology, spatial learning, and cerebral
glucose metabolism.
Methods: Transgenic P301S (n = 33) and wild-type (n = 18) female mice were imaged by 18F-GE-180 TSPO μPET at
the ages of 1.9, 3.9, and 6.4 months. We conducted behavioral testing in the Morris water maze, 18F-
fluordesoxyglucose (18F-FDG) μPET, and AT8 tau immunohistochemistry at 6.3–6.7 months. Terminal microglial
immunohistochemistry served for validation of TSPO μPET results in vivo, applying target regions in the brainstem,
cortex, cerebellum, and hippocampus. We compared the results with our historical data in amyloid-β mouse
models.
Results: TSPO expression in all target regions of P301S mice increased exponentially from 1.9 to 6.4 months,
leading to significant differences in the contrasts with wild-type mice at 6.4 months (+ 11–23%, all p < 0.001), but
the apparent microgliosis proceeded more slowly than in our experience in amyloid-β mouse models. Spatial
learning and glucose metabolism of AT8-positive P301S mice were significantly impaired at 6.3–6.5 months
compared to the wild-type group. Longitudinal increases in TSPO expression predicted greater tau accumulation
and lesser spatial learning performance at 6.3–6.7 months.
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Conclusions: Monitoring of TSPO expression as a surrogate of microglial activation in P301S tau transgenic mice by
μPET indicates a delayed time course when compared to amyloid-β mouse models. Detrimental associations of
microglial activation with outcome parameters are opposite to earlier data in amyloid-β mouse models. The
contribution of microglial response to pathology accompanying amyloid-β and tau over-expression merits further
investigation.
Keywords: TSPO, PET, Tau, Microglia, P301S, Spatial learning, Glucose metabolism
Introduction
Along with features such as extracellular accumulation
of amyloid-β plaques and neuroinflammation, the intracel-
lular aggregation of misfolded tau protein as neurofibrillary
tangles (NFT) constitutes one of the neuropathological hall-
marks of Alzheimer disease (AD) [1]. Under physiological
circumstances, the microtubule-associated protein tau
(MAPT) plays an important role in binding and stabilizing
microtubules, regulating axonal transport, interacting with
filaments of the cellular cytoskeleton, and probably also
contributes to DNA/RNA protection in the nucleus [2]. In
AD and non-AD tauopathies, though, the natively soluble
and unfolded tau protein undergoes a conformational
change via mechanisms such as hyperphosphorylation and
misfolding, leading to diminished physiological functions of
tau and its accumulation as NFT [3–5]. Deposition of
hyperphosphorylated tau in brain is associated with neuro-
inflammation [5], which may exacerbate the ongoing tauo-
pathy and amyloid-β accumulation, while aggravating
neuronal degeneration [4, 5]. Indeed, the neuroinflamma-
tion in AD shows spatial overlap with deposition of
amyloid-β and NFT accumulation [6]. Furthermore, par-
ticular components of the neuroinflammatory cascade pro-
mote the development of NFT [7]. Importantly, the onset
of neuroinflammation occurs early in tauopathies, suggest-
ing that biomarkers of neuroinflammation might serve as a
tool to predict the individual disease course [8].
The transgenic P301S mouse model accumulates tau
in the brainstem [9–11], hippocampus [10, 12], and
cerebral cortex [10], and this accumulation is accompan-
ied by a decline in spatial learning [12]. Immunohisto-
chemical (IHC) analysis revealed increased microglial
activation in transgenic P301S mice at 5 months of age,
compared to findings in wild-type mice [13]. Other stud-
ies demonstrate the capacity of wild-type mouse micro-
glia to phagocytize NFTs accumulating in the brain of
P301S mice [14] and likewise in cultured neurons from
P301S mice [15], consistent with a dual role of micro-
glial activation in exerting neuroprotective [14] and neu-
rodegenerative effects [15]. However, the time course of
microglial neuroinflammation and its net effect on neu-
rodegeneration is not yet established in this mouse
model of tauopathy.
Because understanding the role of neuroinflammation
in AD and non-AD tauopathies is of crucial importance,
we undertook longitudinal monitoring of microglial acti-
vation in P301S mice by means of 18F-GE-180 μPET
in vivo, extending a technique we have established in
amyloid-β mouse models. The tracer 18F-GE-180 binds
to the 18 kDa translocator protein (TSPO) expressed in
activated microglial cells in living mouse brain, showing
excellent correlation with ex vivo validation in several
different amyloid-β mouse models [16–19]. We now
aimed to test the predictive value of early microglial acti-
vation in this tau mouse model by undertaking serial
18F-GE-180 μPET until 6.4 months of age, augmented by
analyses of spatial learning with the Morris water maze
test (MWM) and glucose metabolism with 18F-fluorode-
soxyglucose (18F-FDG) μPET. Finally, we made an IHC
examination of tau and microglia by AT8, IBA1, and
CD68 antisera. Moreover, we compared the temporal
kinetics of microglial activation of the tau mouse model
with corresponding findings retrieved from our historical
amyloid-β mouse model studies.
Materials and methods
Animals and study design
All experiments were performed in compliance with the
National Guidelines for Animal Protection, Germany,
and with the approval of the regional animal committee
(Regierung Oberbayern) and were overseen by a veterin-
arian. Animals were housed in a temperature- and
humidity-controlled environment with 12 h light-dark
cycle, with free access to food (Sniff, Soest, Germany)
and water. μPET experiments were carried out in homo-
zygous female human tau P301S mice (n = 33), a mouse
line expressing the human 0N4R tau isoform with the
P301S mutation in exon 10 of the MAPT gene under
control of the murine thy1 promoter [10], whereas con-
trol studies were conducted in age and sex matched
wild-type (WT, n = 18) mice. TSPO μPET examinations
were performed in a longitudinal design at baseline (1.9
months of age) and two follow-up measurements (3.9
and 6.4 months of age) (Fig. 1a). 18F-FDG μPET scans
were conducted at the age of 6.4–6.5 months. The
MWM test was administered at 12 ± 7 days before the
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final TSPO μPET scan in P301S (n = 22) and WT (n = 18)
mice. After recovery of 2–6 days following the final μPET
scans, randomly selected brains from P301S (n = 14) mice
and WT (n = 5) mice were processed for IBA1, CD68, and
AT8 IHC in the brainstem and cortex. Additional IHC
analyses were conducted in small subgroups (n = 3) of
P301S mice and (n = 2) WT mice at 2.7 and 4.8/4.5
months of age. Mice intended for IHC were deeply anaes-
thetized prior to transcardial perfusion with saline
followed by 4% paraformaldehyde and subsequent brain
extraction. Brains were then fixed by immersion in 4%
paraformaldehyde at 4 °C for 10 h and then transfered to
phosphate buffered saline (PBS). Samples were stored in
PBS with 0.01% sodium azide at 4 °C until preparation for
staining. Representative 50 μm thick slices per animal
were then cut in the axial plane using a vibratome (VT
1000 S, Leica, Wetzlar, Germany). We reprocessed histor-
ical μPET 18F-GE-180 scans from amyloid-β APP/PS1
[19] and AppNL-G-F mice [20] for comparison of their lon-
gitudinal microglial activation with present findings asso-
ciated with tau accumulation in P301S mice.
Radiochemistry and μPET Imaging
Radiosynthesis of 18F-GE-180 was performed as previ-
ously described [16], and 18F-FDG was purchased
commercially. μPET imaging was described as reported
previously [16]. In brief, all mice were anesthetized with
isoflurane (1.5%, delivered at 3.5 L/min) and were placed
in the aperture of the Siemens Inveon DPET. 18F-GE-
180 TSPO μPET with an emission window of 60–90 min
p.i. was used to measure cerebral TSPO expression, and
(on another day) 18F-FDG μPET with an emission win-
dow of 30–60min p.i. was used for assessment of cere-
bral glucose metabolism.
μPET image analysis
All analyses were performed using PMOD (V3.5, PMOD
technologies, Basel, Switzerland). After co-registration to
an MRI mouse atlas [17], we conducted intensity
normalization of images to standardized uptake value
(SUV) relative to uptake in the myocardium for 18F-GE-
180 μPET [21] and by conventional SUV calculation for
18F-FDG μPET. Predefined bilateral cortical (CTX, 24
mm3), bilateral hippocampal (HIP, 11 mm3), cerebellum
(CBL, 12 mm3), and brainstem (BRST, 12 mm3) target
volumes of interest (VOIs) were applied for both tracers
(Fig. 1b). We selected these target VOIs based on our
immunohistochemical findings of tau accumulation in
our earlier studies of the P301S mouse model [9–12].
Fig. 1 Study design and methodology. a Schematic illustration of the study design. TSPO μPET was performed at 1.9, 3.9, and 6.4 months of age
and 18F-FDG μPET at 6.4 months. Morris water maze was conducted before the final μPET scan. After the final scans, randomly selected mouse
brains were processed for immunohistochemistry (IHC) analyses. b Target regions used in the study projected on a mouse brain MRI atlas:
bilateral cortical (CTX), bilateral hippocampal (HIP), cerebellar (CBL), and brainstem (BRST) VOIs. c The middle row shows the bilateral nucleus
accumbens (NCL AC) pseudo reference regions projected on mouse brain MRI. Statistical parametric mapping (SPM) shows lacking differences for
18F-FDG and18F-GE-180 in NAC at 6.4 months of age in SUV-scaled images from P301S mice contrasted against WT mice. d Robustness of 18F-GE-
180 TSPO μPET values in analysis groups (total of six groups of P301S and WT mice) for SUV calculation (white) and pseudo reference region
scaling (black) expressed as mean %-CoV (± SD). Error bars indicate SD. BL, baseline; FU, follow-up; SUV, standardized uptake value; SUVR,
standardized uptake value ratio; CoV, coefficient of variance
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Voxel-based comparisons of SUV maps between
groups of P301S and WT mice were performed using
statistical parametric mapping (SPM, described below)
to identify first a suitable reference tissue for μPET
quantification. Here, this criterion is met by any brain
region in which tracer uptake did not differ with geno-
type or age, either for 18F-FDG or for 18F-GE-180. Our
analysis showed that the bilateral nucleus accumbens
(NAC, 10 mm3) served adequately as a pseudo reference
region for calculation of SUV-ratio (SUVR) values for
both μPET tracers (Fig. 1c). We next calculated
target-to-reference tissue SUVRs, i.e., SUVRCTX/NAC,
SUVRHIP/NAC, SUVRCBL/NAC, and SUVRBRST/NAC, for
18F-GE-180 and 18F-FDG μPET. To quantify longitu-
dinal changes in microglia activation, the percentage
change between SUVR at baseline and the last follow-
up scan was calculated. To allow longitudinal analysis
of combined regions of interest, the area under the
curve (AUC) of 18F-GE-180 μPET SUVR between
baseline and the terminal imaging time point was cal-
culated as previously described [22].
SPM analysis
For both tracers, whole-brain voxel-wise comparisons of
SUV and SUVR images between groups of P301S and
WT mice were performed by SPM using SPM8 routines
(Wellcome Department of Cognitive Neurology,
London, UK) as previously established in our group [9].
This analysis was implemented in MATLAB (version
7.1), as adapted from Sawiak et al. [23] for mouse data.
We performed two-sample t tests, setting a significance
threshold of p < 0.05, uncorrected for multiple
comparisons.
Behavioral testing
n = 22 P301S and n = 18 WT mice were subjected to a
MWM test for spatial learning and memory deficits,
which was performed according to a standard protocol
[20]. On training days one through five, each mouse had
to perform four trials per day in the test basin, with
maximum time set to 70 s. The test trial was performed
on day six. For analyses of escape latency and distance
during MWM testing, we used the video tracking soft-
ware EthoVision® XT 13 (Noldus).
Immunohistochemistry
A standard free-floating immunofluorescence (IF) proto-
col was performed in the cortex and brainstem areas
matching the μPET brain regions. As previously de-
scribed [9, 17], fixed 20-μm thick brain sections were
first rinsed either overnight or for 48 h in PBS with 0.2%
Triton X-100 containing one following primary anti-
bodies: rabbit monoclonal IBA1 (1:500. Wako:19-19741),
mouse monoclonal phospho-Tau (Ser202, Thr2015
(AT8), 1:500. Thermofisher: MN1020), and rat monoclo-
nal CD68 (1:500. Bio-rad: MCA1857). After washing in
PBS, sections were then incubated in a combination of
three secondary antibodies (Alexa 488 goat anti-rabbit,
Alexa 594 goat anti-mouse and Alexa 647 goat anti-rat
IgG). For long-term preservation, the labelled slices were
mounted in DAKO fluorescence mounting medium.
Analyses for overall density (OD) and area coverage
(area-%) were carried out by using the free access pro-
gram ImageJ (https://imagej.nih.gov/ij/). The measure-
ments were performed by using images obtained from a
confocal microscope (LSM 780 Axio invers). Acquisi-
tions were performed at × 20 and × 40 objectives in at
least three sagittal sections. The implemented threshold
tool was used for to limit the extracted data to the spe-
cific signal of the primary antibodies (IBA1, CD68, or
AT8). To subtract unspecific signal from the OD, back-
ground staining signal, as obtained from immuno-
negative regions, was deducted. OD per region was
calculated for IBA1 and CD68 whereas the area-% was
calculated for AT8.
Statistics and calculations
Statistical analyses were performed in SPSS (Version 25,
IBM Deutschland GmbH, Ehningen, Germany). The
Kolmogorov-Smirnov test served to evaluate normal dis-
tribution of all data. Coefficients of variation (CoVs)
were calculated as a measure of robustness in group
data.
Two-tailed unpaired t tests were used to compare in-
tergroup readouts (18F-FDG μPET, MWM, and IHC) of
P301S and age-matched WT mice for all normally dis-
tributed readouts. For intergroup comparison of non-
normally distributed readouts, Mann-Whitney U tests
were calculated. Significance levels for intergroup com-
parison of longitudinal TSPO μPET were calculated by a
mixed model repeated measures ANOVA. Effect sizes
between P301S and WT were determined as Cohen’s d.
For correlation analyses, Pearson’s coefficients of correl-
ation (R) were calculated for normally distributed read-
outs. For non-normally distributed readouts, Spearman’s
coefficients of correlation (rS) were calculated. Cortical
TSPO μPET values in P301S were transformed into z-
scores relative to WT findings as described previously
and then plotted as a function of age. Our historical cor-
tical TSPO μPET data of APP/PS1 (n = 17) [19] and
AppNL-G-F (n = 21) [20] mice were reprocessed in the
same way. Staining intensity as a function of age was
likewise calculated for the current AT8 data in P301S
mice and earlier findings of 18F-florbetaben z-score data
in two historical amyloid-β mouse models. For TSPO
μPET, we calculated the AUC of z-scores for all mice
with successful completion of three or more serial μPET
scans. AUC values were adjusted for the maximum z-
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score in the studied period, normalized to the observa-
tion time, and compared between tau and amyloid-β
mice by ANOVA with Tukey post hoc correction. A val-
idation analysis was performed for AUC within the same
age range (2–7 months) of all three models. Division by
the final TSPO z-score was omitted in this analysis due
to limited serial data points. A threshold of p < 0.05 was
considered to be significant for rejection of the null
hypothesis.
Results
TSPO μPET facilitates monitoring of microglial activation
in P301S mice
We first established that microglial activation can be
monitored by longitudinal TSPO μPET imaging in
P301S mice. To obtain robust TSPO μPET measures, we
validated a suitable pseudo reference tissue: among the
various possible regions, SUVR scaled TSPO μPET
values in the nucleus accumbens (SUVRNAC) showed
more robust group results when compared to conven-
tional SUV scaling, as indicated by lower CoVs. For in-
stance, SUVRNAC CoVs in the brainstem were 6 ± 1%
(range, 4 to 7%) whereas the corresponding SUV CoVs
were 21 ± 3%; (range, 16 to 27%; Fig. 1d).
18F-GE-180 SUVR indicated exponential increases with
age for all four target regions in P301S mice and signifi-
cantly weaker comparable increases in WT mice. At 6.4
months, where was significantly elevated TSPO μPET sig-
nal in the cortex (+ 12%, p = 1.0E−6, Cohen’s d = 1.84),
the hippocampus (+ 11%, p = 5.2E−11, Cohen’s d = 2.85),
the brainstem (+ 23%, p = 3.4E−14, Cohen’s d = 3.74), and
the cerebellum (+ 18%, p = 8.6E−13, Cohen’s d = 3.25) of
P301S mice when compared to WT (Fig. 2a). Voxel-wise
analyses at 6.4 months mirrored this finding for 18F-GE-
180, with the most pronounced elevation in the hindbrain
of P301S mice when compared to WT. However, SPM
analysis revealed the first onset of increased 18F-GE-180
SUVR in P301S mice at 3.9 months of age (Fig. 2b). IHC
with the microglial markers IBA1 and CD68 validated
in vivo findings by indicating a similar increase of micro-
glial activation with age in P301S mice when compared to
increases of TSPO PET. Differences between P301S and
WT mice at 6.6–6.7months of age in IHC were also simi-
lar to TSPO μPET for the cortex (IBA1: + 39%, p = 0.011,
Fig. 2 Longitudinal results of TSPO μPET imaging and immunohistochemistry validation. a Age dependent exponential increase of 18 kDa
translocator protein (TSPO) expression in different target regions of the brain of P301S tau model mice. n(P301S/WT) = 1.9 M, 33/18; 3.9 M, 32/17; 6.4
M, 29/17 (Mixed Model RM Anova of P301S vs wild-type per age). b Voxel-wise SPM analysis of TSPO expression in the contrast of P301S vs wild-
type mice at different ages. T-score maps are projected upon an MRI template in sagittal and coronal slices. n equals to a. c Upper row: CD68
immunohistochemistry for the cortex and the brainstem of P301S mice and WT mice at 6.6 M. n(P301S/WT) = 13/5. Lower row: Time dependent
increase of IBA1 immunohistochemistry for the cortex and the brainstem of P301S mice and WT mice. n(P301S/WT) = 2.7 M, 3/2; 4.8 M, 3/2; 6.6 M,
13/5. d Correlation plots of IBA1/CD68 immunohistochemistry and TSPO μPET at 6.4 months of age. n(CTX) = 12, n(BRST) = 11. M, months; OD,
overall density; R, Pearson’s correlation coefficient; rS, Spearman’s correlation coefficient; CTX, cortex; BRST, brainstem; TG, transgenic P301S mice;
WT, wild-type; *p < 0.05; **p < 0.01; ***p < 0.001. All error bars indicate SD
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Cohen’s d = 2.16/CD68: + 12%, p = 0.043, Cohen’s d =
1.29; Fig. 2c) and brainstem (IBA1: + 50%, p = 1.7E−4,
Cohen’s d = 3.12/CD68: + 21%, p = 0.023, Cohen’s d =
1.56). The TSPO μPET signal in the cortex correlated sig-
nificantly with the IHC for the phagocytosis marker CD68
(R = 0.630, p = 0.028), but not with IBA1 (R = − 0.172, p =
0.593) as a general marker of microglial activation,
whereas the TSPO μPET signal in the brainstem corre-
lated with IBA1 (rS = 0.755, p = 0.007) but not with CD68
(R = − 0.063, p = 0.854; Fig. 2d). Table 1 provides a sum-
mary of TSPO μPET and microglia IHC results. Supple-
mental Figure 1 shows IBA1 and CD68 staining at
different ages.
Longitudinal microglial response in P301S mice is
attenuated and delayed when compared to amyloid-β
mouse models
Next, we asked if there are differences in the longitu-
dinal development of microglial activation between the
present tau mice and earlier studies in amyloid-β mouse
models. To this end, we calculated standardized differ-
ences of TSPO μPET in the cortex of P301S, APP/PS1,
and AppNL-G-F mice in comparison to WT and com-
pared TSPO μPET as a function of age between models.
Standardized differences were lower in P301S mice when
compared to both amyloid-β mouse models (Fig. 3a–c).
Longitudinal cortical TSPO μPET increases in the P301S
mice followed a convex quadratic function (y = 0.09x2 −
0.37x + 1.18) whereas cortical TSPO μPET increases in
amyloid-β mouse models were characterized by concave
quadratic functions (AppNL-G-F: y = − 0.10x2 + 2.16x −
4.53; APP/PS1: y = − 0.04x2 + 1.21x − 1.23; Fig. 3a–c).
The TSPO μPET AUCs integrated over time were sig-
nificantly higher in amyloid-β mouse models (AppNL-G-F,
0.79 ± 0.25; APP/PS1, 0.89 ± 0.41) when compared to
P301S mice (0.52 ± 0.25; p = 0.021/p = 0.016) after ad-
justment for the maximum increase at the ultimate age
and normalization to the observation period (Fig. 3d).
Importantly, there were concave quadratic increases over
time for both tau to AT8 staining in P301S (y = − 0.10x2
+ 1.69x − 1.29) and fibrillar Aβ to 18F-florbetaben μPET
imaging in APP/PS1 (y = − 0.04x2 + 1.14x − 3.22) and
AppNL-G-F (y = − 0.04x2 + 0.86x − 2.67) mice. The results
of the full observation periods were validated by a direct
comparison of similar age ranges between all models
(Fig. 3e–h).
Longitudinal microglial activation is associated with poor
outcome parameters in P301S mice
Finally, we endeavored to test if baseline or longitudinal
TSPO μPET can predict neuropathological, behavioral,
and functional outcome measures in P301S mice. To
this end, we recorded tau quantification, a spatial learn-
ing paradigm, and 18F-FDG μPET at the terminal time-
point and correlated these three endpoints with baseline
and longitudinal TSPO μPET readouts. AT8 positive tau
accumulation was confirmed by immunohistochemistry,
which showed regional colocalization with activated
microglia in the cortex and the brainstem (Fig. 4a).
P301S mice aged 6.3 months took twice as long as WT
mice to find the virtual platform in MWM (P301S 39 ±
20 s; WT 20 ± 21 s; p = 3.4E−4) and revealed a lower fre-
quency of crossing the platform area (P301S 1.5 ± 1.2
times, WT 3.3 ± 2.3 times; p = 0.010). Swim speed of
WT mice was significantly faster when compared to
P301S mice (21 ± 2 cm/s vs 14 ± 3 cm/s, p = 4.8E−8).
Therefore, the travelled distance was additonally ana-
lyzed as a readout unbiased from locomotor problems.
Significantly longer travelled distance in P301S mice
when compared to WT (544 ± 268 cm vs 404 ± 414 cm,
p = 0.019) validated the deficits in spatial memory inde-
pendent from beginning locomotor problems (Fig. 4b).
18F-FDG μPET revealed significantly decreased glucose
metabolism of P301S mice compared with WT mice at
6.4–6.5 months of age in the hippocampus (− 6%; p =
1.9E−4) and the brainstem (− 4%; p = 0.002), which was
also mirrored by voxel-wise analyses (Fig. 4c).
Longitudinal increases of the TSPO μPET signal were
positively correlated with AT8 accumulation in the cor-
tex (R = 0.570, p =0.033) and in the brainstem (R =
0.681, p = 0.007, Fig. 5a). Baseline TSPO μPET did not
significantly predict tau accumulation.
Higher TSPO μPET values over time in the cortex and
the hippocampus of P301S mice were associated with
worse performance in MWM at the late stage (escape la-
tency: rS = 0.493; p = 0.038; frequency: rS = − 0.258, p =
0.302; Fig. 5b). Baseline TSPO μPET did not significantly
predict MWM readouts at 6.3 months of age.
Baseline TSPO μPET elevation in the cortex (R = −
0.448; p = 0.028) and in the hippocampus (R = − 0.415;
p = 0.044) of P301S mice at 1.9 months of age predicted
stronger hypometabolism in FDG μPET at 6.4–6.5
months of age (Fig. 5c). On the other hand, longitudinal
increases of the TSPO μPET signal in these regions were
associated with elevated glucose metabolism or pre-
dicted a trend towards elevated glucose metabolism at
6.4–6.5 months of age (Fig. 5c).
Discussion
We report the first longitudinal in vivo μPET imaging
study of microglial activation together with assessment
of multiple outcome parameters in a tau mouse model.
Our data clearly indicate that μPET with the TSPO
tracer 18F-GE-180 gives reliable assessment of microglial
activation in living P301S mice, as proven by the high
correlation with specific IHC markers. Analysis of indi-
vidual TSPO μPET time courses to 6.4 months of age
revealed that microglial activation in the tau model mice
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exponentially increases with age. Importantly, longitu-
dinal elevations of TSPO expression in P301S mice pre-
dicted aggravated tau accumulation and worse
performance in spatial learning. Levels of glucose metab-
olism at the late stage were positively associated with
longitudinal TSPO μPET increases, but early elevations
of TSPO expression predicted stronger hypometabolism
in P301S mice. These findings may be reconciled by
consideration of the ambivalent role of microgliosis in
neurodegeneration, in some circumstances imparting
neuroprotection, and in other circumstances marking a
more aggressive pathology. This dual role is seemingly
decided by the type of pathology (i.e., tau or amyloid-β
over-expression) and the time course.
We show that transfer of TSPO μPET technology from
different amyloid-β mouse models [19, 22, 24] to the
present tau mouse model is feasible without major ca-
veats. As in some former studies [16, 20], we successfully
validated a suitable pseudo reference region for TSPO
μPET in P301S mice, and we were again able to show
that this methodology reduces variance at the group
level. This SUVR approach supported the detection of
robust longitudinal increases of TSPO expression in dif-
ferent target regions of the P301S mouse model, which
were matched with increases of microglial activation
markers measured later by IHC. Furthermore, our μPET
data were validated by direct correlation with IHC at the
terminal time point. Interestingly, the phagocytosis
marker CD68, which indicated the highest association
with TSPO μPET in our earlier study of amyloid-β mice
[19], significantly correlated with TSPO μPET values in
the cortex but not in the brainstem of tau mice. Yet, the
present correlation of 18F-GE-180 TSPO μPET with the
more general activation marker IBA1 in the brainstem
of tau mice could hinge on different microglia pheno-
types and their covariance with TSPO expression in dif-
ferent brain regions [25]. However, we note that several
specific and random factors like regional blood flow or
slice selection could also cause these divergent observa-
tions. Our findings are in line with those of a study
conducting longitudinal μPET with the TSPO tracer
11C-AC-5216 in another tau mouse model (PS19), like-
wise showing time dependent progression of TSPO ex-
pression in the entorhinal cortex and the hippocampus
[26]. Another study of PS19 mice found microglial acti-
vation especially in the hippocampus to occur ahead of
discernible tau accumulation and brain atrophy [27].
This implicates that microglial activation can already be
present in very early phases of AD, when seeding of tau
just begins and is not identifiable by tau IHC yet. This
also suggests that neuroinflammation could be triggered
by non fibrillar components of tau, ending up in a vi-
cious circle in the pathogenesis of AD. However, we
note that many of the complex underlying mechanisms
Fig. 3 Standardized comparison of time courses of microglial activation between tau and amyloid-β mouse models. a–c Longitudinal TSPO
expression in the cortex of tau and amyloid-β mouse models presented as z-score values against WT plotted with fitting as quadratic functions of
age. d Standardized time courses of longitudinal TSPO expression in the cortex as expressed by the area under the curve (AUC) in three different
mouse models. AUC values were normalized to the observation period and scaled by the z-score of the latest time point to control for absolute
differences in TSPO expression of individual mice. e–h Validation analysis in similar age ranges across all three models. AUC values of the
validation analysis (h) were normalized to the observation period but not to the latest time point. P301S: n = 18 mice, 52 data points; AppNL-G-F: n
= 21 mice, 68 data points; APP/PS1: n = 17 mice, 39 data points. Error bars of d and h indicate SD
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and interrelations are not completely discovered yet [3,
5, 28]. Understanding the role of neuroinflammation in
neurodegenerative disorders is of high importance as it
is associated with deposition of NFT, amyloid-β, and
neuronal degeneration. Translational imaging in mouse
models and patients will facilitate to close important re-
search gaps in terms of reciprocal validation and therapy
monitoring.
As there have been no direct comparisons of the time
courses of microglial activation between amyloid-β and
tau mouse models, we put a special focus on contrasting
longitudinal in vivo TSPO expression of P301S mice
against existing data in two common amyloid-β mouse
models. To account for natural progression of microglial
activation in the aging brain of rodents [17], we com-
pared standardized differences (z-scores) in relation to
age among the different mouse models. By this ap-
proach, we are able to show for the first time that tem-
poral kinetics of microglial activation differ depending
on whether it is driven by tau or amyloid-β pathology.
In particular, TSPO expression in response to tau path-
ology showed attenuated and delayed development when
compared to TSPO expression in response to Aβ
overexpression. Importantly, there were similar increases
of the amounts of AT8 positive tau in P301S mice or fi-
brillar Aβ in APP/PS1 and AppNL-G-F mice with age, in-
dicating that the observed differences were not driven by
variant time courses of protein accumulation. In the
translational aspect, the onset of Aβ and tau aggregation
may precede the start of clinical symptoms in human
AD [29], and associations of both proteins with micro-
glial activation have already been shown in human PET
studies [6]. Thus, the presence of amyloid-β and tau
should be considered (i.e., by PET or CSF) when inter-
preting time courses of microglial activation in human
neurodegenerative disease, to avoid bias arising from dif-
ferences in their temporal associations. Furthermore,
more detailed studies comparing tau and amyloid-β
mouse models employing next generation sequencing or
proteomics should resolve possible differences of micro-
glia phenotypes in relation to the two abnormal protein
aggregates.
Details of the role and time dependence of neuroin-
flammation in AD remain a matter of controversy and
debate, given the ambivalence of protective and detri-
mental aspects [3, 28, 30]. This also accounts for some
Fig. 4 Outcome parameter in comparison of P301S and wild-type mice. a Longitudinal accumulation of tau measured via AT8
immunohistochemistry and representative images of co-staining with IBA1 and CD68 in the cortex (upper row) and brainstem (lower row). n (2.7
M/4.8 M) = 3; n (6.6 M) = 14. Scale bar = 30 μm. b Performance of mice in Morris water maze (MWM) at study termination with escape latency,
velocity, swimming distance, and frequency of platform crossing. n = 22 P301S, n = 18 WT. c Glucose metabolism (FDG-PET uptake) in the
different target VOIs at 6.4 months of age and SPM results of the contrast P301S and wild-type (WT) mice. n = 24 P301S, n = 16 WT. Color coding
shows regions with decreased glucose metabolism (T-scores) in P301S mice when compared to WT upon an MRI template in sagittal and coronal
slices, as indicated by red lines in the axial MRI slice. CTX, cortex; HIP, hippocampus; BRST, brainstem; CBL, cerebellum; M, months; SUVR,
standardized uptake value ratio; *p < 0.05; **p < 0.01; ***p < 0.001. All error bars indicate SD
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earlier findings on microglial function in the P301S
mouse model. Luo et al. [14] showed in vitro and
ex vivo the capability of isolated wild-type microglia to
phagocytize tau in brain tissue of P301S mice, implicat-
ing a possible protective effect of fully functional micro-
glia. On the other hand, a recent study of Brelstaff et al.
[15] indicated that activated microglia can phagocytize
neurons of P301S mice and therefore seemingly mediate
deleterious effects. This matches with the setting that
microglial cells can generally be separated into two clas-
ses, proinflammatory (mainly detrimental) and anti-
inflammatory (mainly protective) phenotypes, and can
presumably change from one state to another depending
on the required function [28].
The strength of our data lies in its longitudinal in vivo
design, covering approximately three quarters of the 9-
month lifespan of P301S model mice. The compilation
of data indicates that higher longitudinal TSPO expres-
sion in P301S mice predict higher tau accumulation and
worse spatial learning at 6.4 months of age. Interestingly,
the corresponding associations with glucose metabolism
to 18F-FDG μPET gave different predictions for baseline
and longitudinal measures. While early elevation in
TSPO expression was associated with hypometabolism
at 6.4 months, we observed higher terminal glucose
metabolism in tau mice with TSPO increasing over time.
While the first result suggests an overall deleterious ef-
fect of high early TSPO expression on the outcome of
P301S mice, the second observation is more consistent
with a coupling of microglial activation and glucose me-
tabolism, as observed previously in PS2APP mice [16].
With regard to spatial learning deficits, our earlier study
with congruent methodology and design in PS2APP
amyloid-β mice showed that early microglial activation
in the forebrain strongly correlated with better cognitive
performance in MWM [31]. Speculatively, this could in-
dicate different predictive capability of TSPO μPET de-
pending on whether tau or amyloid-β accumulation is
the primary driver of microgliosis. Regarding tau mouse
models, our observation of higher tau accumulation in
mice with early microglial activation is in line with find-
ings of associated tau and neuroinflammation in the
forebrain of rTg4510 tau mice [32]. Our data also fit
with the observations of attenuated NFT accumulation,
reduced neuronal degeneration, and averted cognitive
deterioration after pharmacological ablation of senescent
microglial and astroglial cells in PS19 mice [33], as well
as fitting with the increased tau pathology occurring
along with NLRP3 inflammasome activation [7]. In sum-
mary, tau-associated microglial activation seems more
Fig. 5 Associations of early and longitudinal microglial activation with outcome parameters. a Correlation of longitudinal TSPO expression in
P301S mice (expressed as %-increase between 1.9 and 6.4 months of age) with accumulation of AT8 positive tau accumulation in IHC for the
cortex and the brainstem; n = 14. b Correlation of combined longitudinal TSPO expression in cortex and hippocampus (calculated as AUC) with
terminal MWM performance; n = 18. c Correlations of early and longitudinal TSPO expression (BL z-score and %-increase) with terminal glucose
metabolism (FDG PET z-score) for the cortex and the hippocampus; n = 24
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detrimental than amyloid-β-associated effects. Import-
antly, our compilation of findings of amyloid-β and tau
mouse models may help support a model wherein the
net effect of neuroinflammation changes from being ini-
tially protective (A+/T−) to deleterious in late phases
(A+/T+) of AD [34]. Among the limitations of our study,
we note that we did not perform longitudinal TSPO-
PET imaging in male mice. Thus, we cannot evaluate ef-
fects of sex on the current results. We acknowledge a
gap of 1 week in average between the final PET scan and
IHC which might has a limited impact on correlation
analyses between both modalities since microglial activa-
tion in P301S mice raises with aging.
Conclusions
Monitoring of microglial activation in P301S tau trans-
genic is feasible by μPET with the TSPO tracer 18F-GE-
180 TSPO, as validated by IHC with microglial markers.
P301S mice manifest delayed time courses and detri-
mental associations of their microglial activation with
outcome parameters when compared to earlier data of
amyloid-β mouse models. This should draw further at-
tention to the study of phenotypic differences of the
microglial responses to amyloid-β and tau accumulation.
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